Denali Advisors’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Denali Advisors’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3,320	Closed	-$203K	–	413
2020 Q2	$203K	Buy	3,320 +420	+14%	+$24.3K	0.04%	250
2020 Q1	$164K	Sell	2,900 -41	-1%	-$2.34K	0.04%	214
2019 Q4	$167K	Buy	+2,941	New	+$156K	0.02%	226
2019 Q3	–	Sell	-26	Closed	-$2K	–	341
2019 Q2	$2K	Hold	26	–	–	﹤0.01%	286
2019 Q1	$2K	Sell	26 -23	-47%	-$1.52K	﹤0.01%	241
2018 Q4	$3K	Sell	49 -21	-30%	-$1.25K	﹤0.01%	192
2018 Q3	$4K	Buy	70 +15	+27%	+$765	﹤0.01%	180
2018 Q2	$2K	Hold	55	–	–	﹤0.01%	255
2018 Q1	$2K	Buy	55 +33	+150%	+$1.39K	﹤0.01%	247
2017 Q4	$1K	Buy	+22	New	+$989	﹤0.01%	262
2015 Q4	–	Sell	-27	Closed	-$1K	–	317
2015 Q3	$1K	Buy	+27	New	+$1.46K	﹤0.01%	285

Other funds holding BSTC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Denali Advisors's BSTC Position: Q3 2020 in Review

Denali Advisors sold out of BioSpecifics Technologies Corp. (BSTC) in Q3 2020, closing a stake of 3,320 shares — an estimated $203K sold.

Denali Advisors first reported a position in BSTC in Q3 2015 and held it in 11 quarters. The position peaked at $203K in Q2 2020. 113 funds tracked by Wall St. Rank hold BSTC as of Q3 2020.

Denali Advisors reported no remaining BioSpecifics Technologies Corp. position as of Q3 2020 after selling out during the quarter.
Denali Advisors sold 3,320 BioSpecifics Technologies Corp. shares in Q3 2020, an estimated $203K.
Denali Advisors first reported a position in BioSpecifics Technologies Corp. in Q3 2015 and held it in 11 quarters.
Denali Advisors's BioSpecifics Technologies Corp. position peaked at $203K in Q2 2020.
113 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q3 2020.

Based on Denali Advisors's 13F filing for Q3 2020, filed 16 Oct 2020.